About Rznomics
Rznomics is a company based in Yongin (South Korea) founded in 2017 by Seong-Wook Lee. Rznomics has raised $39.8 million across 2 funding rounds from investors including SBI Mutual Fund, SBI Investment Korea and Korea Development Bank Europe. Rznomics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics and Revolution Medicines, among others.
- Headquarter Yongin, South Korea
- Founders Seong-Wook Lee
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rznomics Inc.
-
Annual Revenue
$4.91 M (USD)0as on Dec 31, 2025
-
Net Profit
-$72.41 M (USD)-455.13as on Dec 31, 2025
-
EBITDA
-$24.5 M (USD)-39as on Dec 31, 2022
-
Total Equity Funding
$39.8 M (USD)
in 2 rounds
-
Latest Funding Round
$29.76 M (USD), Series C
Jun 08, 2022
-
Investors
SBI Mutual Fund
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Rznomics
Rznomics is a publicly listed company on the KRX with ticker symbol 476830 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Rznomics
Rznomics has successfully raised a total of $39.8M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $29.76 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rznomics
Rznomics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include SBI Mutual Fund, SBI Investment Korea and Korea Development Bank Europe.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment services are offered by AON Investment in Seoul.
|
Locked | Locked | Locked | |
|
PE firm investing in South Korea and the US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Rznomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rznomics
Investment portfolio details for Rznomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rznomics
Detailed financials for Rznomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rznomics Comparisons
Peer comparison for Rznomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rznomics
Rznomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
Detailed competitors of Rznomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rznomics
Complete news archive for Rznomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rznomics
Rznomics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Rznomics is headquartered in Yongin, South Korea. It is registered at Yongin, Gyeonggi, South Korea.
Seong-Wook Lee is the current CEO of Rznomics. They have also founded this company.
Rznomics is a funded company, having raised a total of $39.8M across 2 funding rounds to date.
Annual revenue of Rznomics is $4.91M as on Dec 31, 2025.
Rznomics was founded in 2017 as a biotechnology firm specializing in RNA platform technology for drug development. Gene therapy products are created to address cancers, degenerative conditions, hereditary liver diseases, and related disorders. Operations focus on innovative treatments, with lead candidates including RZ001 for cancer, RZ002, and RZ003 targeted at Alzheimers disease. The company operates within the pharmaceutical sector, emphasizing RNA-based solutions for unmet medical needs.
Rznomics's top competitors include Moderna, Jazz Pharmaceuticals and Spark Therapeutics.
Yes, Rznomics is publicly traded on KRX under the ticker symbol 476830.
Rznomics has 11 investors. Key investors include SBI Mutual Fund, SBI Investment Korea, Korea Development Bank Europe, AON Investment, and Partners Investment.
The ticker symbol of Rznomics is 476830 on KRX.